Gut Microbiota-A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review

doi:10.3390/ijms23158307

Review

. 2022 Jul 27;23(15):8307.

doi: 10.3390/ijms23158307.

Gut Microbiota-A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review

Roberta Forlano¹, Mathuri Sivakumar², Benjamin H Mullish¹, Pinelopi Manousou¹

Affiliations

¹ Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London W2 1NY, UK.
² Faculty of Medicine, University of Birmingham, Birmingham B15 2TT, UK.

PMID: 35955434
PMCID: PMC9368436
DOI: 10.3390/ijms23158307

Review

Gut Microbiota-A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review

Roberta Forlano et al. Int J Mol Sci. 2022.

. 2022 Jul 27;23(15):8307.

doi: 10.3390/ijms23158307.

Authors

Roberta Forlano¹, Mathuri Sivakumar², Benjamin H Mullish¹, Pinelopi Manousou¹

Affiliations

¹ Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London W2 1NY, UK.
² Faculty of Medicine, University of Birmingham, Birmingham B15 2TT, UK.

PMID: 35955434
PMCID: PMC9368436
DOI: 10.3390/ijms23158307

Abstract

Non-alcoholic fatty liver disease (NAFLD) represents an increasing cause of liver disease, affecting one-third of the population worldwide. Despite many medications being in the pipeline to treat the condition, there is still no pharmaceutical agent licensed to treat the disease. As intestinal bacteria play a crucial role in the pathogenesis and progression of liver damage in patients with NAFLD, it has been suggested that manipulating the microbiome may represent a therapeutical option. In this review, we summarise the latest evidence supporting the manipulation of the intestinal microbiome as a potential therapy for treating liver disease in patients with NAFLD.

Keywords: FMT; NAFLD; NASH; microbiome; probiotic.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

**Figure 1**
Flowchart of the study for the systematic review.

See this image and copyright information in PMC

Cited by

Changes in the intestinal microbiota of individuals with non-alcoholic fatty liver disease based on sequencing: An updated systematic review and meta-analysis.
Cai W, Qiu T, Hu W, Fang T. Cai W, et al. PLoS One. 2024 Mar 28;19(3):e0299946. doi: 10.1371/journal.pone.0299946. eCollection 2024. PLoS One. 2024. PMID: 38547205 Free PMC article.
Short-chain fatty acids in nonalcoholic fatty liver disease: New prospects for short-chain fatty acids as therapeutic targets.
Li X, He M, Yi X, Lu X, Zhu M, Xue M, Tang Y, Zhu Y. Li X, et al. Heliyon. 2024 Feb 27;10(5):e26991. doi: 10.1016/j.heliyon.2024.e26991. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38486722 Free PMC article. Review.
Advancements in metabolic-associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions.
Eeda V, Patil NY, Joshi AD, Awasthi V. Eeda V, et al. Hepatol Res. 2024 Mar;54(3):222-234. doi: 10.1111/hepr.14008. Epub 2024 Jan 22. Hepatol Res. 2024. PMID: 38149861 Review.
Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.
Jayachandran M, Qu S. Jayachandran M, et al. Rev Endocr Metab Disord. 2023 Dec;24(6):1189-1204. doi: 10.1007/s11154-023-09843-z. Epub 2023 Oct 16. Rev Endocr Metab Disord. 2023. PMID: 37840104 Review.
Lactiplantibacillus plantarum LPJZ-658 Improves Non-Alcoholic Steatohepatitis by Modulating Bile Acid Metabolism and Gut Microbiota in Mice.
Liu L, Deng L, Wei W, Li C, Lu Y, Bai J, Li L, Zhang H, Jin N, Li C, Zhao C. Liu L, et al. Int J Mol Sci. 2023 Sep 12;24(18):13997. doi: 10.3390/ijms241813997. Int J Mol Sci. 2023. PMID: 37762300 Free PMC article.

See all "Cited by" articles

References

1. Younossi Z., Tacke F., Arrese M., Chander Sharma B., Mostafa I., Bugianesi E., Wai-Sun Wong V., Yilmaz Y., George J., Fan J., et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019;69:2672–2682. doi: 10.1002/hep.30251. - DOI - PubMed
1. Pydyn N., Miekus K., Jura J., Kotlinowski J. New therapeutic strategies in nonalcoholic fatty liver disease: A focus on promising drugs for nonalcoholic steatohepatitis. Pharm. Rep. 2020;72:1–12. doi: 10.1007/s43440-019-00020-1. - DOI - PubMed
1. Farrell G.C., Wong V.W., Chitturi S. NAFLD in Asia—As common and important as in the West. Nat. Rev. Gastroenterol. Hepatol. 2013;10:307–318. doi: 10.1038/nrgastro.2013.34. - DOI - PubMed
1. Benedict M., Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J. Hepatol. 2017;9:715–732. doi: 10.4254/wjh.v9.i16.715. - DOI - PMC - PubMed
1. Musso G., Gambino R., Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: An update. Obes. Rev. 2010;11:430–445. doi: 10.1111/j.1467-789X.2009.00657.x. - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

This research received no external funding.

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Younossi Z., Tacke F., Arrese M., Chander Sharma B., Mostafa I., Bugianesi E., Wai-Sun Wong V., Yilmaz Y., George J., Fan J., et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019;69:2672–2682. doi: 10.1002/hep.30251. - DOI - PubMed

[2] Younossi Z., Tacke F., Arrese M., Chander Sharma B., Mostafa I., Bugianesi E., Wai-Sun Wong V., Yilmaz Y., George J., Fan J., et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019;69:2672–2682. doi: 10.1002/hep.30251. - DOI - PubMed

[3] Pydyn N., Miekus K., Jura J., Kotlinowski J. New therapeutic strategies in nonalcoholic fatty liver disease: A focus on promising drugs for nonalcoholic steatohepatitis. Pharm. Rep. 2020;72:1–12. doi: 10.1007/s43440-019-00020-1. - DOI - PubMed

[4] Pydyn N., Miekus K., Jura J., Kotlinowski J. New therapeutic strategies in nonalcoholic fatty liver disease: A focus on promising drugs for nonalcoholic steatohepatitis. Pharm. Rep. 2020;72:1–12. doi: 10.1007/s43440-019-00020-1. - DOI - PubMed

[5] Farrell G.C., Wong V.W., Chitturi S. NAFLD in Asia—As common and important as in the West. Nat. Rev. Gastroenterol. Hepatol. 2013;10:307–318. doi: 10.1038/nrgastro.2013.34. - DOI - PubMed

[6] Farrell G.C., Wong V.W., Chitturi S. NAFLD in Asia—As common and important as in the West. Nat. Rev. Gastroenterol. Hepatol. 2013;10:307–318. doi: 10.1038/nrgastro.2013.34. - DOI - PubMed

[7] Benedict M., Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J. Hepatol. 2017;9:715–732. doi: 10.4254/wjh.v9.i16.715. - DOI - PMC - PubMed

[8] Benedict M., Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J. Hepatol. 2017;9:715–732. doi: 10.4254/wjh.v9.i16.715. - DOI - PMC - PubMed

[9] Musso G., Gambino R., Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: An update. Obes. Rev. 2010;11:430–445. doi: 10.1111/j.1467-789X.2009.00657.x. - DOI - PubMed

[10] Musso G., Gambino R., Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: An update. Obes. Rev. 2010;11:430–445. doi: 10.1111/j.1467-789X.2009.00657.x. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Gut Microbiota-A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review

Affiliations

Gut Microbiota-A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Research Materials